Adam D. Cohen, MD

Adam D. Cohen, MD, assistant professor of medicine, director, Myeloma Immunotherapy, University of Pennsylvania, discusses the ongoing phase II DREAMM-2 study in multiple myeloma. 

Prior to the trial, the phase I DREAMM-1 study demonstrated an overall response rate (ORR) of 60% with the investigational antibody-drug conjugate (ADC) belantamab mafodotin (GSK2857916). 

DREAMM-2 is a registration study that is evaluating the ADC in a heavily pretreated and refractory population, explains Cohen. To be eligible for enrollment, patients had to have been exposed to a proteasome inhibitor, an immunomodulatory drug, and a CD38-targeted antibody.  

In the trial, patients will be randomized to receive 3.4 mg/kg or 2.5 mg/kg of intravenous belantamab mafodotin. According to topline findings reported in a press release, belantamab mafodotin resulted in a clinically meaningful ORR in patients with relapsed myeloma, meeting the primary endpoint of the trial.

Videos

Adam D. Cohen, MD, discusses the ongoing phase II DREAMM-2 study in multiple myeloma. 
 

Author | Adam D. Cohen, MD

Articles

Dr. Cohen on the DREAMM-2 Trial in Multiple Myeloma